New 20-Strain pneumonia vaccine tested in chinese seniors

NCT ID NCT07019909

Completed ⭐️ VACCINE ⭐️ Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new 20-valent pneumococcal vaccine (20vPnC) against an existing 13-valent vaccine in 400 adults aged 50 and older in China who had never received a pneumococcal vaccine. The goal was to check safety and immune response. Results will help decide if the broader-coverage vaccine is safe enough for larger trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 20-valent pneumococcal conjugate vaccine (20vPnC) and 13-valent pneumococcal conjugate vaccine (13vPnC)
What this could lead to: If successful, this could lead to a new vaccine that protects against more strains of pneumococcal disease, potentially reducing infections in older adults.
What could go wrong: This is an early Phase 1 trial with only 400 participants, so results may not apply to everyone. The main focus is safety, not yet proof of effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PNEUMOCOCCAL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pneumococcal infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PNEUMOCOCCAL DISEASE

Contacts and locations

Locations

Kaihua County Center For Disease Prevention and Control

Kaihua, Zhejiang, 324300, China
Kaihua County Center For Disease Prevention and Control

Quzhou, Zhejiang, 324300, China
Zhejiang provincial center for disease control and prevention

Hangzhou, Zhejiang, 310051, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.